Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Axcan Pharma |
---|---|
Information provided by: | Axcan Pharma |
ClinicalTrials.gov Identifier: | NCT00110968 |
Itopride is a compound already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms of functional dyspepsia. Patients suffering from this condition have difficulties digesting food. Patients feel full after eating, they have bloating and have stomach pain. The goal of this study is to see if Itopride helps to relieve the symptoms of functional dyspepsia on a long-term basis.
Condition | Intervention | Phase |
---|---|---|
Dyspepsia |
Drug: Itopride hydrochloride |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multicentre, Open-Label Extension Phase to Study the Long-Term Safety and Efficacy of Itopride HCl in Patients Suffering From Functional Dyspepsia |
Estimated Enrollment: | 300 |
Study Start Date: | September 2004 |
Study Completion Date: | September 2006 |
Primary Completion Date: | July 2006 (Final data collection date for primary outcome measure) |
All patients having completed study ITOFD04-01 will be offered to continue to be treated with itopride for a period of up to one year in duration. A target of 300 patients will be followed up for 6 months. Of these, a target of 100 patients will be kept on treatment for an additional 6 months.
Patients will need to come to the clinic for evaluations every 8 weeks during the trial. Evaluations done at these visits will include: lab tests, evaluation of the heartburn condition, and a questionnaire needed to be completed by the patient to see if the drug is helpful in relieving their symptoms.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Axcan Pharma inc. ( Monique Giguère ) |
Study ID Numbers: | ITOFD04-02 |
Study First Received: | May 16, 2005 |
Last Updated: | July 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00110968 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Abdominal Symptom relief Fullness Bloating Indigestion Functional dyspepsia |
Signs and Symptoms Stomach Diseases Digestive System Diseases Signs and Symptoms, Digestive |
Gastrointestinal Diseases Gastroenteritis Dyspepsia Gastritis |
Signs and Symptoms Stomach Diseases Digestive System Diseases Signs and Symptoms, Digestive |
Gastrointestinal Diseases Gastroenteritis Dyspepsia Gastritis |